Chinese-US Bridge Luye Pharma USA serves as the U.S. clinical and regulatory arm for Luye, offering a bridge for cross-border regulatory strategy and market access, which can be leveraged to accelerate introductions of Luye’s oncology and CNS products into the US market.

Small Cell Focus Recent launches of Zepzelca (lurbinectedin) for small cell lung cancer in Hong Kong and Macao indicate a strong portfolio in oncology that can be parlayed into U.S. business development conversations around similar compound classes and regulatory pathways.

Regulatory Hub As a regulatory and clinical hub with a presence in China, the USA, and Europe, Luye Pharma USA can support partner companies seeking global development, regulatory strategy, and potential co-development or in-licensing opportunities in oncology and CNS.

Growth via Partnerships Strategic collaborations, such as past distribution partnerships and BeiGene co-commercialization efforts, suggest openness to licensing, distribution, and co-development deals that could expand Luye’s footprint in mainland China and across Asia with US-based sponsors.

Mid-market Potential With a revenue range of 25–50 million and a lean U.S. team, Luye Pharma USA presents an opportunity for growth-focused alliances, channel partnerships, and sponsored research or advisory roles that scale efficiently without large organizational overhead.